327 related articles for article (PubMed ID: 11374225)
1. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis].
Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I
Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225
[TBL] [Abstract][Full Text] [Related]
2. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial.
Ahsan N
Adv Perit Dial; 2000; 16():80-4. PubMed ID: 11045266
[TBL] [Abstract][Full Text] [Related]
3. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
4. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
5. ITDI is the preferred treatment for iron supplementation in rHuEpo-treated anemic PD patients.
Ahsan N
Adv Perit Dial; 1998; 14():228-31. PubMed ID: 10649730
[TBL] [Abstract][Full Text] [Related]
6. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
7. [Iron supplementation during erythropoietin therapy in patients on hemodialysis].
Svára F; Sulková S; Kvasnićka J; Polakovic V
Vnitr Lek; 1996 Dec; 42(12):849-52. PubMed ID: 9072885
[TBL] [Abstract][Full Text] [Related]
8. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
9. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
[TBL] [Abstract][Full Text] [Related]
10. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
Raja R; Bloom E; Johnson R; Goldstein M
Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
[TBL] [Abstract][Full Text] [Related]
11. Assessment of iron deficiency in chronic hemodialysis patients: investigation of cutoff values for reticulocyte hemoglobin content.
Mitsuiki K; Harada A; Miyata Y
Clin Exp Nephrol; 2003 Mar; 7(1):52-7. PubMed ID: 14586744
[TBL] [Abstract][Full Text] [Related]
12. Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients.
Fischer MA; Morris CA; Winkelmayer WC; Avorn J
Arch Intern Med; 2007 Apr; 167(8):840-6. PubMed ID: 17452549
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
Raja R; Bloom E; Johnson R
Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
[TBL] [Abstract][Full Text] [Related]
14. Importance of iron saturation for erythropoietin responsiveness in chronic peritoneal dialysis.
Jonnalagadda V; Bloom EJ; Raja RM
Adv Perit Dial; 1997; 13():113-5. PubMed ID: 9360662
[TBL] [Abstract][Full Text] [Related]
15. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
[TBL] [Abstract][Full Text] [Related]
16. Management of anemia in erythropoietin-resistant hemodialysis patients.
Dar Santos AE; Shalansky KF; Jastrzebski JP
Ann Pharmacother; 2003 Dec; 37(12):1768-73. PubMed ID: 14632604
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
18. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
19. The efficiency of fractionated parenteral iron treatment in CAPD patients.
Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A
Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661
[TBL] [Abstract][Full Text] [Related]
20. Reticulocyte hemoglobin content in hemodialysis patients with acute infection.
Mitsuiki K; Harada A; Miyata Y
Clin Exp Nephrol; 2004 Sep; 8(3):257-62. PubMed ID: 15480904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
